Skip to main content
Erschienen in: International Journal of Diabetes in Developing Countries 2/2019

07.06.2018 | Original Article

Association between plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and lipids with rs7903146 polymorphisms of the TCF7L2 gene in diabetic patients

verfasst von: Rohollah Yousefi, Narges Mohammadtaghvaei, Mehrnoosh Zakerkish, Hamid Yaghooti, Ali Karimi Akhormeh, Ramin Tavakoli

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The rs7903146 polymorphism of TCF7L2 gene is known as the strongest genetic risk factor for type 2 diabetes mellitus (T2DM). The polymorphism is in association with clinical profile of T2DM patients. PCSK9 is a serine protease that promotes LDLR degradation and regulates circulating levels of lipids. The association of this polymorphism with PCSK9 and metabolic profile of diabetic and healthy subjects was investigated. This cross-sectional study was performed on 132 T2DM patients and the same number of healthy subjects. All the participants were genotyped for the rs7903146 single nucleotide polymorphism by the PCR-RFLP method. Metabolic profile including plasma levels of PCSK9, triglycerides, total cholesterol, non-HDL cholesterol, LDL cholesterol, HDL cholesterol, fasting plasma glucose, and HBA1C was measured. PCSK9, total cholesterol, and LDL-C levels were lower in the diabetic patients as compared to the healthy subjects. There were also direct and significant associations between PCSK9 and TG, TC, LDL-C, and non HDL-C in the subjects. Values of plasma glucose, HbA1c, PCSK9, TC, and LDL-C were higher in patients with TT genotype, but the differences were not statistically significant for all. A positive Spearman correlation was found between PCSK9 levels and the genotypes in all the participants. The results confirm the association of rs7903146 in the TCF7L2 gene with metabolic parameters and PCSK9. The T allele was associated with higher lipid and PCSK9 levels.
Literatur
1.
Zurück zum Zitat Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med. 2007;85:685–96.CrossRefPubMed Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med. 2007;85:685–96.CrossRefPubMed
2.
Zurück zum Zitat Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A. 2008;105:1820–5.CrossRefPubMedPubMedCentral Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A. 2008;105:1820–5.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007;8:718–32.CrossRefPubMed Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007;8:718–32.CrossRefPubMed
4.
Zurück zum Zitat Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol. 2007;18:304–9.CrossRefPubMed Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol. 2007;18:304–9.CrossRefPubMed
5.
Zurück zum Zitat Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Hirano T, et al. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipid Health Dis. 2016;15(1):165.CrossRef Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Hirano T, et al. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipid Health Dis. 2016;15(1):165.CrossRef
6.
Zurück zum Zitat Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.CrossRef Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.CrossRef
7.
Zurück zum Zitat Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol. 2014;174:863–4.CrossRefPubMed Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol. 2014;174:863–4.CrossRefPubMed
8.
Zurück zum Zitat Li JJ, Li YS, Fang CH, et al. Effects of simvastatin within two weeks on antiinflammatory cytokine interleukin 10 in patients with unstable angina. Heart. 2006;92:529e30.CrossRef Li JJ, Li YS, Fang CH, et al. Effects of simvastatin within two weeks on antiinflammatory cytokine interleukin 10 in patients with unstable angina. Heart. 2006;92:529e30.CrossRef
9.
Zurück zum Zitat Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.CrossRef Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.CrossRef
10.
Zurück zum Zitat Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009;55(9):1637–45.CrossRefPubMed Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009;55(9):1637–45.CrossRefPubMed
11.
Zurück zum Zitat Brouwers MCGJ, Troutt JS, van Greevenbroek MMJ, Ferreira I, Feskens EJ, van der Kallen C, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis. 2011;217(1):263–7.CrossRefPubMed Brouwers MCGJ, Troutt JS, van Greevenbroek MMJ, Ferreira I, Feskens EJ, van der Kallen C, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis. 2011;217(1):263–7.CrossRefPubMed
12.
Zurück zum Zitat Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537–43.CrossRefPubMedPubMedCentral Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537–43.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type2 diabetic patients. J Diabetes Complicat. 2015;29(8):1165–70.CrossRefPubMed Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type2 diabetic patients. J Diabetes Complicat. 2015;29(8):1165–70.CrossRefPubMed
14.
Zurück zum Zitat Yang SH, Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, et al. Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes. Diabetes Metab Res Rev. 2016;32(2):193–9.CrossRefPubMed Yang SH, Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, et al. Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes. Diabetes Metab Res Rev. 2016;32(2):193–9.CrossRefPubMed
15.
Zurück zum Zitat Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7- like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–3.CrossRefPubMed Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7- like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–3.CrossRefPubMed
16.
Zurück zum Zitat Buraczynska M, Swatowski A, Markowska-Gosik D, Kuczmaszewska A, Ksiazek A. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and complication/comorbidity profile in type 2 diabetes patients. Diabetes Res Clin Pract. 2011;93(3):390–5.CrossRefPubMed Buraczynska M, Swatowski A, Markowska-Gosik D, Kuczmaszewska A, Ksiazek A. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and complication/comorbidity profile in type 2 diabetes patients. Diabetes Res Clin Pract. 2011;93(3):390–5.CrossRefPubMed
17.
Zurück zum Zitat Sousa AG, Marquezine GF, Lemos PA, Martinez E, Lopes N, Hueb WA, et al. TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PLoS One. 2009;4(11):e7697.CrossRefPubMedPubMedCentral Sousa AG, Marquezine GF, Lemos PA, Martinez E, Lopes N, Hueb WA, et al. TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PLoS One. 2009;4(11):e7697.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM, et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med. 2006;20(4):34.CrossRef Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM, et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med. 2006;20(4):34.CrossRef
19.
Zurück zum Zitat Warodomwichit D, Arnett DK, Kabagambe EK, Tsai MY, Hixson JE, Straka RJ, et al. Polyunsaturated fatty acids modulate the effect of TCF7L2 gene variants on postprandial Lipemia. J Nutr. 2009;139:439–46.CrossRefPubMedPubMedCentral Warodomwichit D, Arnett DK, Kabagambe EK, Tsai MY, Hixson JE, Straka RJ, et al. Polyunsaturated fatty acids modulate the effect of TCF7L2 gene variants on postprandial Lipemia. J Nutr. 2009;139:439–46.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Levenson AE, Shah AS, Khoury PR, Kimball TR, Urbina EM, de Ferranti SD, et al. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatr Diabetes. 2017;18(8):755–60.CrossRefPubMedPubMedCentral Levenson AE, Shah AS, Khoury PR, Kimball TR, Urbina EM, de Ferranti SD, et al. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatr Diabetes. 2017;18(8):755–60.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Miao J, Manthena PV, Haas ME, Ling AV, Shin DJ, Graham MJ, et al. Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9. Arterioscler Thromb Vasc Biol. 2015;35(7):1589–96.CrossRefPubMedPubMedCentral Miao J, Manthena PV, Haas ME, Ling AV, Shin DJ, Graham MJ, et al. Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9. Arterioscler Thromb Vasc Biol. 2015;35(7):1589–96.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Rangel SR, Araújo EM, de Matos EM, Carvalho G, Rios DLS. THE rs7903146 SNP of TCF7L2 gene and its association with the metabolic syndrome a review. Braz J Med Human Health. 2014;2(3):111–22. Rangel SR, Araújo EM, de Matos EM, Carvalho G, Rios DLS. THE rs7903146 SNP of TCF7L2 gene and its association with the metabolic syndrome a review. Braz J Med Human Health. 2014;2(3):111–22.
23.
Zurück zum Zitat Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010;59:479–85.CrossRefPubMed Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010;59:479–85.CrossRefPubMed
24.
Zurück zum Zitat Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117(8):2155–63.CrossRefPubMedPubMedCentral Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117(8):2155–63.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 2006;281(10):6211–8.CrossRefPubMed Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 2006;281(10):6211–8.CrossRefPubMed
26.
Zurück zum Zitat Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49:399–409.CrossRefPubMed Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49:399–409.CrossRefPubMed
27.
Zurück zum Zitat Ibarretxe D, Girona J, Plana N, Cabré A, Ferré R, Amigó N, et al. Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. Clin Investig Arterioscler. 2016;28(2):71–8.PubMed Ibarretxe D, Girona J, Plana N, Cabré A, Ferré R, Amigó N, et al. Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. Clin Investig Arterioscler. 2016;28(2):71–8.PubMed
28.
Zurück zum Zitat Yang SH, Li S, Zhang Y, Xu RX, Zhu CG, Guo YL, et al. Analysis of the association between plasma PCSK9 and Lp (a) in Han Chinese. J Endocrinol Invest. 2016;39(8):875–83.CrossRefPubMed Yang SH, Li S, Zhang Y, Xu RX, Zhu CG, Guo YL, et al. Analysis of the association between plasma PCSK9 and Lp (a) in Han Chinese. J Endocrinol Invest. 2016;39(8):875–83.CrossRefPubMed
29.
Zurück zum Zitat Wang S, Song K, Srivastava R, Fathzadeh M, Li N, Mani A. The protective effect of transcription factor 7-like 2 risk allele rs7903146 against elevated fasting plasma triglyceride in type 2 diabetes: a meta-analysis. J Diabetes Res. 2015;2015:468627.PubMedPubMedCentral Wang S, Song K, Srivastava R, Fathzadeh M, Li N, Mani A. The protective effect of transcription factor 7-like 2 risk allele rs7903146 against elevated fasting plasma triglyceride in type 2 diabetes: a meta-analysis. J Diabetes Res. 2015;2015:468627.PubMedPubMedCentral
30.
Zurück zum Zitat Perez-Martinez P, Perez-Caballero AI, Garcia-Rios A, Yubero-Serrano EM, Camargo A, Gomez-Luna MJ, et al. Effects of rs7903146 variation in the Tcf7l2 gene in the lipid metabolism of three different populations. PLoS One. 2012;7(8):e43390.CrossRefPubMedPubMedCentral Perez-Martinez P, Perez-Caballero AI, Garcia-Rios A, Yubero-Serrano EM, Camargo A, Gomez-Luna MJ, et al. Effects of rs7903146 variation in the Tcf7l2 gene in the lipid metabolism of three different populations. PLoS One. 2012;7(8):e43390.CrossRefPubMedPubMedCentral
Metadaten
Titel
Association between plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and lipids with rs7903146 polymorphisms of the TCF7L2 gene in diabetic patients
verfasst von
Rohollah Yousefi
Narges Mohammadtaghvaei
Mehrnoosh Zakerkish
Hamid Yaghooti
Ali Karimi Akhormeh
Ramin Tavakoli
Publikationsdatum
07.06.2018
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 2/2019
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-018-0647-9

Weitere Artikel der Ausgabe 2/2019

International Journal of Diabetes in Developing Countries 2/2019 Zur Ausgabe